GeneNews provides Lilly with access to its osteoarthritis biomarker program
TORONTO, CANADA (October 27, 2009):
GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has entered into an agreement allowing Eli Lilly and Company (NYSE: LLY) select access to research from its osteoarthritis genomic biomarker program. Terms of the agreement were not disclosed.
“Our recently patented platform technology for the discovery of blood-based biomarkers, the Sentinel Principle®, can be applied to identify biomarkers for virtually any disease or condition and was extensively validated in our osteoarthritis program,” said Dr. Heiner Dreismann, Lead Director and Interim CEO of GeneNews. “This agreement brings us together with our third multi-national partner and is a positive reflection of the quality of our work and experience in creating value for GeneNews and our partners.”
Eli Lilly and Company is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Indiana, Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs.
Forward-Looking Statements
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.
